Long-Acting HIV Treatment and Prevention Are Coming: Defining the Intended Market for New Products

Policy makers will need to assess a range of critical issues that will influence whether and when individuals can and will choose to use these new products.

Read report here.

In partnership with amfAR, the O’Neill Institute published a series of issue briefs. The briefs provide examination of critical policy issues that impact access, availability and acceptability of PrEP and long-acting agents, which are innovative forms of PrEP and HIV treatments that are under development and do not require daily pill taking. The series of briefs highlight the education and policy dialogues needed to prepare for innovative long-acting products transmission and reduce health care spending.

 Read all four reports in this series here.